Brian Park, PharmD

Drug Information Specialist https://www.thecardiologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Cardiology

PENS Device Cleared to Treat Pain Following Cardiac Surgery

Brian Park, PharmD

September 29, 2022

Approval was based on a prospective study that evaluated the effectiveness of the Primary Relief device in 60 patients who underwent cardiac surgery.

Metabolic

NIH Study Compares Four Commonly Used Type 2 Diabetes Medications

Brian Park, PharmD

September 28, 2022

The multicenter, randomized, controlled GRADE study was designed to compare the effectiveness of 4 major FDA-approved medications.

Cannabis and its synthetic cannabinoids have been studied for medicinal properties across multiple d

News

CDC: Increase in Adverse Events Linked to Delta-8 THC Products

Brian Park, PharmD

September 17, 2021

The delta-8 THC products have not been evaluated or approved by FDA for safe use in any context.

News

Chantix Recalled, Distribution Halted Over Nitrosamine Impurity

Brian Park, PharmD

July 8, 2021

Long-term use of a product containing N-nitroso-varenicline may be associated with an increased cancer risk based on data from closely related nitrosamine compounds.

General Cardiology

Finerenone Improves Cardiovascular Outcomes in Diabetic Kidney Disease

Brian Park, PharmD

May 12, 2021

The study evaluated finerenone in addition to standard of care in patients with chronic kidney disease and type 2 diabetes.

Uncategorized

Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease

Brian Park, PharmD

October 29, 2020

The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial.

cardiovascular disease, CVD, heart disease, MRI

Heart Failure

Canagliflozin Approved to Reduce CV Death Risk in Adults With T2D and Nephropathy

Brian Park, PharmD

October 1, 2019

The FDA has approved a new indication for Invokana to reduce the risk of end-stage renal disease, doubling of serum creatinine, CV death, and more in T2D.

Heart Failure

Neuromodulation Device Approved for Patients With Advanced Heart Failure

Brian Park, PharmD

August 22, 2019

The FDA has approved the Barostim Neo System (CVRx, Inc.) for the improvement of symptoms of heart failure.

Next post in Heart Failure